Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

62
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
62
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

62
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
62
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

376
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
376
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

1.0K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.0K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

267
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
267
Complement System01:27

Complement System

11.3K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Frontiers in immunology·2026
Same author

C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab.

Kidney medicine·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same author

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Health technology assessment (Winchester, England)·2026
Same author

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

The Lancet regional health. Europe·2026
Same author

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

Kidney international reports·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
Same journal

Advancing science and care in CKD-MBD: the layered path to legacy.

Current opinion in nephrology and hypertension·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.7K

Update on evaluating complement in hemolytic uremic syndrome.

David Kavanagh1, Timothy H Goodship

  • 1Renal Division, Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.

Current Opinion in Nephrology and Hypertension
|December 20, 2007
PubMed
Summary
This summary is machine-generated.

Genetic discoveries have illuminated atypical hemolytic uremic syndrome (aHUS). Understanding complement factor mutations improves prognosis prediction and guides future complement inhibitor therapies for aHUS patients.

More Related Videos

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.2K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

39.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.7K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.2K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

39.0K

Area of Science:

  • Genetics
  • Nephrology
  • Immunology

Background:

  • The genetic basis of atypical hemolytic uremic syndrome (aHUS) has been progressively decoded.
  • Complement factor H mutations were the first identified genetic link to aHUS.

Purpose of the Study:

  • To review recent advancements in understanding the genetic underpinnings of aHUS.
  • To highlight the prognostic significance of genetic screening in aHUS management.

Main Methods:

  • Review of recent scientific literature on aHUS genetics.
  • Analysis of newly described complement gene associations with aHUS.
  • Examination of genotype-phenotype correlations and their clinical implications.

Main Results:

  • A transgenic mouse model lacking complement factor H C-terminus spontaneously develops aHUS.
  • Genotype-phenotype correlations reveal differing prognoses based on specific gene mutations (MCP, CFH, CFI).
  • New aHUS-associated complement genes identified include factor B, C3, C4b-binding protein, FHR1, and FHR3.

Conclusions:

  • Genetic screening in aHUS provides crucial prognostic information for survival, renal recovery, and transplant outcomes.
  • Established genotype-phenotype correlations aid in predicting patient trajectories.
  • These genetic insights pave the way for targeted complement inhibitor therapies in aHUS.